Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with classical Hodgkin lymphoma at stage 3 or 4 who have not yet received any systemic treatment (steroid medications taken for symptom relief are acceptable)
• People whose lymphoma can be measured on scans, according to standard measurement guidelines called the Lugano criteria
• People whose doctors consider them suitable to receive 6 cycles of a combination chemotherapy regimen that includes a type of drug called an anthracycline
• People who show no signs of lymphoma affecting the brain or spinal cord
• People who are reasonably physically functional, rated 0 to 2 on a standard medical scale called the ECOG performance status (confirm with trial site)
• People whose blood cell counts meet minimum levels set by the trial, including white blood cells, platelets, and red blood cells — with some flexibility if low counts are caused by the lymphoma itself
• People whose kidney function results fall within the acceptable range set by the trial
• People whose liver function results fall within the acceptable range set by the trial (with some exceptions for certain liver conditions, such as Gilbert Syndrome)
• People aged 18 or older
• People who are willing and expected to complete all planned treatment in the study
• People who have given written informed consent after being told about the investigational nature of the trial
• Male participants who agree to use an adequate barrier contraception method from the first dose of treatment until 120 days after the last dose
• Female participants of childbearing potential who have a negative pregnancy test (urine or blood) within 72 hours before starting treatment
• Female participants of childbearing potential who agree to use 2 forms of birth control, or who are surgically sterile, or who abstain from heterosexual activity, from the start of the study until 120 days after the last dose

Who may not be able to join:

• People who are known to be HIV positive with a detectable viral load (those living with HIV who are on antiviral treatment with an undetectable viral load may still be considered)
• People with hepatitis B or C with a detectable viral load (those with certain hepatitis B or C markers but an undetectable viral load and appropriate medical management may still be considered)
• People who are currently pregnant or breastfeeding, or people of reproductive potential who are not willing to use effective contraception
• People who have had another cancer in the past, unless it was a skin cancer of a specific type that was adequately treated, an early-stage breast or cervical cancer that was treated, or any other cancer from which the person has been free of disease for 2 or more years (exceptions may be considered by the principal investigator)
• People who have other serious health conditions that would make intensive chemotherapy unsafe, such as an active serious infection, uncontrolled high blood pressure, heart failure, unstable chest pain, a heart attack within the past 6 months, an uncontrolled irregular heartbeat, severe lung disease, or a current need for supplemental oxygen
• People with active ischemic heart disease (such as a heart attack within the past 6 months) or heart failure with reduced heart pumping function
• People currently receiving other cancer treatments or experimental therapies
• People with a known current or previous autoimmune disease (exceptions include vitiligo, and autoimmune thyroid disease that is well controlled on a stable dose of thyroid hormone)
• People with a history of lung inflammation (pneumonitis or interstitial lung disease) that previously required steroid treatment, or who currently have this condition
• People who currently require supplemental oxygen
• People who have received a live or live-attenuated vaccine within the 30 days before the first dose of trial treatment (non-live vaccines such as COVID-19 or flu vaccines are acceptable)

Important: Always verify eligibility with the trial site directly before applying.